Asia Pacific Next Generation Sequencing Ngs In Cancer Diagnostic Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 684.99 Million |
 Market Size (Forecast Year) |
USD 2,184.50 Million |
 CAGR |
% |
| Major Markets Players |
亚太地区癌症诊断市场的下一代测序 (NGS)，按癌症类型（肺癌、乳腺癌、结直肠癌、前列腺癌、胃癌、宫颈癌、白血病等）、产品和服务（试剂盒、软件、服务和仪器）、技术（面板/靶向测序和重测序、全外显子组测序、全基因组测序、RNA 测序和其他测序技术）、工作流程（NGS 测序、NGS 数据分析和 NGS 预测序）、应用（筛查、伴随诊断等）、最终用户（病理实验室、医院、肿瘤中心等）、分销渠道（直接招标和零售销售）– 行业趋势和预测到 2030 年。
亚太地区癌症诊断市场下一代测序 (NGS) 分析及规模
新一代测序 (NGS) 为肿瘤个性化医疗带来了巨大发展。新一代技术可以节省时间和成本地对癌症 DNA 进行测序，从而改变癌症治疗研究。个性化医疗和肿瘤学的改进预计将对市场产生重大影响。在临床环境中部署 NGS 提供了几种有趣的可能性。因此，所有这些都对市场增长产生了重大影响。
Data Bridge Market Research 分析了 2023-2030 年预测期内癌症诊断市场中下一代测序 (NGS) 的增长率。在上述预测期内，癌症诊断市场中下一代测序 (NGS) 的预期复合年增长率约为 15.6%。2022 年市场价值为 6.8499 亿美元，到 2030 年将增长至 21.845 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
亚太地区下一代测序 (NGS) 在癌症诊断市场的范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
Cancer Type (Lung, Breast, Colorectal, Prostrate, Stomach, Cervical, Leukemia, and Others), Product and Service (Kits, Software, and Services and Instruments), Technologies (Panels/Targeted Sequencing and Resequencing, Whole Exome Sequencing, Whole Genome Sequencing, RNA Sequencing, and Other Sequencing Technologies), Workflow (NGS Sequencing, NGS Data Analysis, and NGS Pre-Sequencing), Application (Screening, Companion Diagnostics, and Others), End User (Pathology Labs, Hospitals, Oncology Centers and Others), Distribution Channel (Direct Tender and Retail Sales) |
|
Countries Covered |
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC) |
|
Market Players Covered |
Illumina, Inc. (U.S.), Thermo Fisher Scientific (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies Inc. (U.S.), Myriad Genetics Inc. (U.S.), BGI (China), Perkin Elmer Inc. (U.S.), Foundation Medicine Inc. (U.S.), PacBio (U.S.), Oxford Nanopore Technologies plc. (U.K.), Paradigm Diagnostics Inc. (U.S.), Caris Life Sciences (Japan), Partek, Incorporated (U.S.), Eurofins Scientific (Luxembourg), QIAGEN (Germany) |
|
Market Opportunities |
|
Market Definition
Next-generation sequencing or NGS, is also known as high-throughput sequencing. It is a technology that utilizes extreme parallelization to gather enormous DNA strands. The innovation reduces the requirement for segment cloning, a step in Sanger genome sequencing. NGS also creates precision medicine for treating patients with varied illnesses.
Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market Dynamics
Drivers
- Growing Use in Agri-Genomics Research and Increasing Healthcare Expenditure
Several plants and animals use NGS as a genomic tool, which is expected to increase the market's expansion. In India's GDP for the year 2018, agriculture was a close second to mining at 17%. Rice, sugarcane, and eucalyptus are new examples of current applications of NGS to extract genetic variation for crop improvement. Large populations of specimens can be screened promptly by NSG. Several new plant species can be domesticated instantly with the growing application of NSG, which also helps to identify and collect novel genetic variation from closely associated species. Thus, this factor boosts market growth.
Opportunities
- Increasing Application in Precision Oncology
The increase in clinical applications of next-generation sequencing in precision oncology has boosted the efforts of the major market players to develop novel platforms that can be used widely for genomic assays. For instance, Congenica collaborated with Gabriel Precision Oncology Ltd. to manufacture an automatic clinical oncology interpretation software platform. Thus, this factor boosts market growth.
- Rising Demand for Targeted Cancer Sequencing Panels
Increasing demand for targeted cancer sequencing panels is extensively increasing the market's growth. Targeted cancer sequencing panels help decrease the time, cost, and amount of data analyzed while sequencing tumor samples. Furthermore, the increasing efficiency of targeted panels to identify malignant tumors improves their clinical utility. As per a study published in JCO Precision Oncology, 2020, NGS panels are clinically useful in 64% of cancer cases. Thus, this factor increases the growth of the market.
Restraints/Challenges
- High Cost of Genomic Technology
High cost, along with technology, is a major hindrance to the market's growth during the forecast period. High costs associated with poor outsourced service efficiency, installation of different sequencing platforms, and little availability of sequencing platforms are all expected to limit the development of next-generation sequencing in the cancer diagnostic market. All these factors hamper the growth of the market.
This next generation sequencing (NGS) in cancer diagnostic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the next generation sequencing (NGS) in cancer diagnostic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2020, Burning Rock Biotech Limited, a China-based cancer test provider, entered into a partnership with Illumina to promote the standardization and development of NGS-based cancer therapy selection within China. The company also signed an agreement with Myriad Genetics, Inc. to develop and commercialize myChoice tumor testing in China.
Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market Scope
The next generation sequencing (NGS) in cancer diagnostic market is segmented on the basis of cancer type, product and service, technologies, workflow, application, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Cancer Type
- Lung
- Breast
- Colorectal
- Prostrate
- Stomach
- Cervical
- Leukemia
- Others
Product and Service
- Kits
- Software and Services
- Instruments
Technologies
- Panels/Targeted Sequencing and Resequencing
- Whole Exome Sequencing
- Whole Genome Sequencing
- RNA Sequencing
- Other Sequencing Technologies
Workflow
- NGS Sequencing
- NGS Data Analysis
- NGS 预测序
应用
- 筛查
- 伴随诊断
- 其他的
最终用户
- 病理学实验室
- 医院
- 肿瘤中心
- 其他的
分销渠道
- 直接招标
- 零售销售
癌症诊断市场中的下一代测序 (NGS) 区域分析/见解
对癌症诊断市场中的下一代测序 (NGS) 进行了分析，并按上述癌症类型、产品和服务、技术、工作流程、应用、分销渠道和最终用户提供了市场规模洞察和趋势。
癌症诊断市场下一代测序（NGS）报告涵盖的主要国家 是亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）其他地区。
由于分子生物学技术的进步，预计中国在预测期内的增长率最高。它改进了测序方法，预计这将提高市场增长。该国的主要参与者以比其他国家更具竞争力的价格提供 NGS 产品和服务
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了亚太地区品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
亚太地区癌症诊断下一代测序 (NGS) 市场竞争格局及份额分析
癌症诊断市场竞争格局中的下一代测序 (NGS) 提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、亚太地区业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司在癌症诊断市场中对下一代测序 (NGS) 的关注有关
癌症诊断市场中下一代测序 (NGS) 的主要参与者包括：
- Illumina 公司（美国）
- 赛默飞世尔科技公司（美国）
- F. Hoffmann-La Roche Ltd.（瑞士）
- 安捷伦科技公司（美国）
- Myriad Genetics Inc.（美国）
- BGI（中国）、Perkin Elmer Inc.（美国）
- Foundation Medicine Inc.（美国）
- PacBio (美国)
- 牛津纳米孔技术有限公司（英国）
- Paradigm Diagnostics Inc.（美国）
- Caris Life Sciences（日本）
- Partek, Incorporated（美国）
- Eurofins Scientific（卢森堡）
- QIAGEN（德国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
